Pyxis Oncology reports 36% cORR, 6.2-month mPFS, 79% 12-month OS probability
Pyxis Oncology reported a 36% confirmed objective response rate and 6.2-month median PFS for MICVO in 2L+ recurrent/metastatic head and neck squamous cell carcinoma.
Key Highlights:Original SEC Filing: Pyxis Oncology, Inc. [ PYXS ] - 8-K - Sep. 09, 2026This is an AI-powered summary. It may contain i…